At-home allergy shots: the evidence and the safeguards
Understand what a selected home-SCIT study found, why major allergy guidance favors clinic administration, and what a physician must resolve before home injections.
At-home allergy shots require a prescribed environmental-allergy SCIT program, clinical selection, training, supervision and an emergency plan—not DIY injections. The AAAAI/ACAAI practice parameter prefers an equipped medical facility and limits home use to rare exceptional circumstances. A retrospective UAS study reported 37 systemic reactions among 23,614 selected patients and 2,021,600 injections in one year, including one grade III and one grade IV reaction and no deaths. Those results are not Curex outcomes. Curex describes physician-supervised home shots with care-manager support; confirm current enrollment, eligibility and the actual initiation safeguards directly with the care team.
· Last verified: October 5, 2026
The clinical distinction
At-home allergy shots exist, but they are not DIY treatment
Allergy shots—subcutaneous immunotherapy, or SCIT—expose a patient to prescribed environmental allergens by injection to reduce allergic symptoms over time. Home administration changes where the injection happens; it does not remove the need for diagnosis, a physician-designed prescription, training, monitoring or an emergency plan. It is not a treatment for food allergy, and a prescription for drops is not a prescription for injections.
Curex describes an environmental-allergy shot program prescribed by allergy physicians, prepared by a specialty pharmacy and supported online by a physician and care manager, without weekly clinic visits. That description explains the service model. It does not by itself establish a reaction rate, demonstrate equivalence to every office protocol, or mean that home injections are appropriate for everyone.
The key tension deserves a direct answer: the AAAAI/ACAAI practice parameter favors injections in a medical facility and restricts home administration to rare, exceptional circumstances. A large study of a selected, practice-supervised home-SCIT population reported low reaction rates, but did not overturn that guideline or test Curex. Both facts matter when deciding what setting is appropriate.
What major allergy guidance says about the setting
The 2011 AAAAI/ACAAI allergen immunotherapy practice parameter, summary statements 62–65, recommends direct supervision in a facility equipped to recognize and treat anaphylaxis. The preferred setting is the prescribing physician's office, with another appropriately equipped medical facility an option. Patients should remain under observation for at least 30 minutes after an office injection, and delayed reactions remain possible.
Its home-administration exception is narrow: when immunotherapy cannot be administered in a medical facility and withholding it would seriously harm the patient, benefits and risks should be considered individually, informed consent obtained, and another adult trained to administer treatment and respond to anaphylaxis. The example is venom immunotherapy for a patient in a remote region—not ordinary scheduling convenience for environmental shots. The parameter states: “Frequent or routine prescription of home immunotherapy is not appropriate under any circumstances.”
A 2020 AAAAI work-group report, written for the COVID-19 outbreak, repeated that home administration is strongly discouraged except for rare and special circumstances. It is not a recommendation for routine telemedicine home-SCIT. Ask any home-shot prescriber how the proposed care plan addresses this position and why an office-based option is or is not appropriate for you.
The home-SCIT safety study: exact denominators and reported results
Schaffer and colleagues' primary publication, PMID 25476041 / PMC4465093, published online in 2014 and in the 2015 journal issue, reviewed the United Allergy Services protocol during a one-year period in 2011–2012. This was a retrospective record review of selected patients with seasonal or perennial allergic rhinitis, not a randomized home-versus-office trial.
| Measure | Reported result | How to interpret it |
|---|---|---|
| Patient denominator | 23,614 patients approved for self-administered SCIT | These were screened participants in the UAS program, not all patients interested in allergy shots. |
| Injection denominator | 2,021,600 self-administered injections | The paper’s reported total for the one-year analysis; do not confuse injections with patients. |
| Systemic reactions | 37 reported systemic reactions; 0.16% per patient and 0.002% per injection (rounded) | The patient rate describes the studied year, not lifetime risk. The injection rate is not a guarantee for an individual dose. |
| Severity | 18 grade I, 17 grade II, 1 grade III and 1 grade IV reaction; no grade V deaths | Serious reactions did occur. Zero observed deaths is not evidence that death or anaphylaxis is impossible. |
| Timing | 19 early-onset reactions and 18 delayed reactions occurring after 30 minutes | Both the grade III and grade IV reactions were delayed; readiness matters beyond an initial observation window. |
| Population | 18,971 adults and 4,643 children aged 5–17 | Pediatric inclusion does not prove suitability for younger children or establish Curex’s shot-program age criteria. |
The main analysis is the 23,614-patient / 2,021,600-injection cohort. The paper’s separate description of a longer program history is not the denominator for these annual reaction rates.
The safeguards were part of the intervention
The study methods are as important as its percentages. The program did not simply send vials to untrained patients. These are descriptions of that UAS protocol, not verified Curex operating procedures or instructions to copy.
- Preselection. Patients were diagnosed using history, examination, environmental assessment and skin testing. Severe or uncontrolled asthma, significant cardiovascular disorders and beta-blocker use were among the contraindications addressed by screening.
- Initial office-based SCIT and competence assessment. All patients began with office-based treatment, instruction in epinephrine use and supervised self-administration. Office injections included a 30-minute observation period. Those who did not meet home-administration standards stayed on an office-based regimen.
- A trained treatment partner and epinephrine. An “IT partner” familiar with the regimen, vial storage and epinephrine administration had to be present for every home injection. Epinephrine had to be available.
- A slower build-up. The protocol used a six-month build-up rather than a rapid escalation approach. This is study context, not a recommended schedule for a reader or evidence that Curex uses the identical protocol.
- Reporting and re-evaluation. Reactions were reported to the clinic; no further injection was permitted until the clinic gave instructions. If treatment continued after a reaction, subsequent injections could return to the clinic under physician supervision.
- Monthly clinical contact. Patients returned with dosing logs for review and collected a limited supply of unit-dose vials. This practice-based oversight differs from assuming that a remote-only prescription reproduces the study conditions.
Why those results cannot become a Curex safety claim
The study’s findings concern the UAS protocol, the selected population and the reporting system in that period. Patient selection, dose escalation, office initiation, partner requirements and follow-up can all affect the observed risk. A telemedicine service cannot borrow the published rate merely because it also offers home injections.
The analysis depended on reported reactions and retrospective clinical records. It did not randomize comparable patients to home and office treatment. Comparisons with reaction rates in earlier office studies involved different populations, schedules and ascertainment. Those comparisons do not establish that home administration is safer than office administration, or that an individual should leave a supervised clinic.
Several study authors listed UAS affiliations. UAS also has an existing article describing the publication; that is a provider account of its own evidence, not another independent study or an endorsement of Curex. Read the primary paper first. No Curex-specific SCIT outcome publication is supplied by these sources.
Curex’s environmental-allergy cohort, PMID 42358593, studied sublingual drops in 2,897 adults with at least 12 months of follow-up, not allergy shots. It cannot establish the safety, dose-error rate or effectiveness of Curex’s home-SCIT program.
Curex’s described offering and what to confirm before enrollment
Curex’s supplied company description identifies at-home environmental allergy shots as a service, with an allergist-designed schedule, specialty-pharmacy preparation, care-manager check-ins and physician supervision online. Patients keep epinephrine available. It describes testing through a local lab, at-home phlebotomist or self-collection kit, with existing test results accepted for physician review.
Use the existing Curex allergy shots page and contact the care team to confirm current enrollment, your state, your age and clinical eligibility. A general statement that Curex serves all 50 states is not proof that every program is enrolling every patient in every state. Do not use an old waitlist description—or a general service description—as an individual enrollment decision.
Before starting, ask who performs the clinical training and competence assessment, where initial supervised doses occur, who must be with you during injections, and how observation and emergency response are arranged. Those initiation details must come from the actual prescriber; this manuscript does not assume Curex duplicates the UAS study’s office-based start or monthly office visits. If the proposed safeguards differ, ask for the clinical rationale and evidence.
Who needs an in-person assessment before considering home injections?
- Anaphylaxis or previous systemic shot reactions. A history of anaphylaxis or a systemic reaction to immunotherapy warrants an in-person allergist evaluation, not a self-directed switch to home dosing.
- Uncontrolled asthma or changing respiratory symptoms. Asthma must be appropriately controlled. New wheezing or an exacerbation changes the dosing decision; obtain the prescriber’s written hold rules and contact the team rather than proceeding as usual.
- Significant medical conditions or relevant medication use. Disclose cardiovascular disease, beta-blockers and all other medicines. These can affect risk or response to emergency treatment. Do not stop a prescribed medication on your own to qualify.
- Children or pregnancy. Children need an age-appropriate in-person assessment and reliable adult supervision. Pregnancy requires individualized review; allergen immunotherapy is usually not initiated during pregnancy, and continuation is a prescriber decision.
- Suspected food or drug allergy. Environmental SCIT is not an evaluation or treatment pathway for these problems. Seek an in-person allergist assessment; food challenges are never a home procedure.
- Missing practical safeguards. If trained help, epinephrine, suitable storage, reliable records or prompt emergency access cannot be maintained, tell the physician. A prescription or desire to avoid travel does not resolve those barriers.
The practical tradeoff: travel versus immediate clinical support
- Potential convenience.Avoiding repeated injection trips can matter for work, childcare or long travel distances. Treatment still requires a planned routine and a multi-year commitment—not occasional injections whenever convenient.
- More responsibility at the dosing site.The patient and trained partner must follow the actual prescription, recognize reactions, maintain supplies and records, and know how to activate emergency care. An online care manager is not a resuscitation team in the room.
- Product-specific handling.Follow pharmacy instructions for storage, shipment problems and beyond-use dates. Do not apply allergy-drop storage advice to injectable vials.
- Immediate clinical response.A properly equipped office has trained personnel, medications and equipment to recognize and treat anaphylaxis. This is the reason for the guideline preference, not simply a billing convention.
- Observed administration.Staff can check the patient’s current condition, prescription and reaction history before dosing and observe afterward. New vials, interruptions and reactions can be managed directly.
- Travel and coverage considerations.Visits and observation take time, particularly during build-up. In-office shots may be covered by insurance, subject to plan benefits; do not assume home injections receive the same coverage.
A safety plan is not a dose guide
Never start injections from an article, video or generic schedule. Do not mix or dilute extracts, share vials, convert drop doses to shot doses, transfer an office prescription home without approval, or increase a dose yourself. Even experienced shot patients need a prescriber-approved transition with records of formulation, dose history and previous reactions.
Obtain written instructions covering illness, asthma symptoms, missed injections, a reaction, a new vial, a damaged shipment and a lapse in required supervision. Hold dosing when the prescriber’s plan requires it; if you are uncertain whether the current dose is authorized, contact the team before injecting. Restarting or adjusting treatment after a reaction belongs to the prescriber.
Make sure you and the trained partner know how to recognize anaphylaxis, use prescribed epinephrine and call 911. Breathing difficulty, throat swelling or faintness cannot wait for a portal reply. Reactions can occur after the initial observation period. Epinephrine and a partner reduce response barriers, but they do not make the home environment equivalent to an equipped clinic.
Regulation, cost and the decision to make with your physician
FDA-licensed allergenic extracts are used for injection immunotherapy, but approval of an extract does not constitute approval of a particular compounded mixture, home-administration service or remote-supervision protocol. The practice parameter notes that extract labeling implies clinical-setting administration. Compounded sublingual drops are a separate product: they are not FDA-approved, and extract approval does not approve the sublingual route or formulation. The Curex FDA correspondence record and 2021 FDA untitled letter provide the drops-related documents.
Ask for a program-specific cost estimate covering serum, training or initiation visits, clinician follow-up, epinephrine, supplies, shipping and any required in-person care. Curex accepts insurance for testing and consultations, but benefits, deductibles and network status matter. A headline price for drops or a general starting price is not a home-shot quote.
The decision is not “shots are dangerous” versus “home is always safe.” It is whether SCIT is appropriate, which setting fits the patient’s risk, and whether the actual program has a defensible clinical plan. Discuss office-based SCIT and other suitable options with an allergist before making the switch. The published UAS data are relevant context, not a substitute for that decision.
âť“Frequently Asked Questions
No. SCIT needs a clinical diagnosis, an individualized prescription and a physician-approved administration plan. Do not buy, mix, dilute or inject extracts on your own, or take an office vial home without approval. Training, a trained treatment partner, epinephrine and an emergency plan do not replace clinical selection and supervision.
No. The 2011 AAAAI/ACAAI practice parameter favors administration in an appropriately equipped medical facility and limits home administration to rare, exceptional circumstances when withholding treatment would seriously harm the patient. A 2020 AAAAI work-group report reiterated that position. Convenience alone is not the exception described by that guidance.
The one-year retrospective analysis reported 37 systemic reactions among 23,614 selected patients receiving 2,021,600 self-administered injections: rounded rates of 0.16% per patient and 0.002% per injection. There were 18 grade I, 17 grade II, one grade III and one grade IV reaction, with no grade V deaths. These are study-period results, not zero lifetime risk or a Curex reaction rate.
No. It did not randomize comparable patients to home and clinic care. Its population was screened and used a slower build-up, initial office treatment, a trained partner, epinephrine and monthly clinic review. Comparisons with earlier office studies cannot establish that changing the injection setting makes treatment safer.
Curex’s company description identifies an environmental-allergy home-shot service with physician supervision and care-manager support. Confirm current enrollment, your state, age and eligibility directly with the care team using the existing allergy-shots page. General nationwide service availability does not guarantee every program is enrolling every patient.
Use the prescriber’s written hold and contact instructions; do not catch up, escalate or restart on your own. A reaction needs reporting and clinical reassessment before further injections. For suspected anaphylaxis, use prescribed epinephrine as directed and call 911 immediately rather than waiting for an online response.
General information, not individualized medical advice. Your treating clinician decides eligibility, treatment and dosing. For trouble breathing, throat swelling, faintness or a suspected severe allergic reaction, follow your prescribed emergency plan and call 911.
Sources
Written by Curex editorial team. Medical review has not been recorded.
- Schaffer et al.: primary home-SCIT safety publication (PMC4465093; PMID 25476041)
- AAAAI/ACAAI: allergen immunotherapy practice parameter, 2011, statements 62–65
- AAAAI: 2020 SCIT administration work-group report, home administration position
- UAS: provider account of its own published home-SCIT evidence
- UAS: current allergy-shot protocol description
- Curex supplied company source of truth: About Us — Curex, September 29, 2026 (editorial document)
- Curex allergy shots page; current enrollment must be confirmed
- Curex environmental SLIT cohort; not SCIT outcome evidence (PMID 42358593)
- FDA: March 23, 2021 untitled letter to Curex about drops